Tilray Brands
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Tilray Brands and other ETFs, options, and stocks.About TLRY
Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness.
TLRY Key Statistics
Stock Snapshot
With a market cap of 1.71B, Tilray Brands(TLRY) trades at $14.77. The stock has a price-to-earnings ratio of -0.57.
On 2025-12-18, Tilray Brands(TLRY) stock moved within a range of $12.95 to $15.69. With shares now at $14.77, the stock is trading +14.1% above its intraday low and -5.9% below the session's peak.
Trading volume for Tilray Brands(TLRY) stock has reached 15.38M, versus its average volume of 24.64M.
The stock's 52-week range extends from a low of $3.51 to a high of $23.20.
The stock's 52-week range extends from a low of $3.51 to a high of $23.20.
TLRY News
Shares of Tilray Brands (TLRY) moved back into positive territory after slipping earlier this week. The latest swings came after President Trump confirmed that...
Tilray Brands (NASDAQ:TLRY), global medical cannabis producer, closed Tuesday’s session at $13.94, up 27.54%. Trading volume reached 46.8 million shares, about...
Tilray Brands (TLRY) just rode a wave of optimism after reports that President Trump plans to reclassify marijuana to Schedule III, a potential game changer for...
Analyst ratings
80%
of 10 ratingsMore TLRY News
Tilray Brands recently announced that its Redecan unit launched Amped Live Resin Liquid Diamond 1g 510 cartridges in Canada, while also promoting a broad 2025 h...
If you are wondering whether Tilray Brands is finally a smart buy or just another volatile cannabis story, you are not alone. That is exactly what we are going...
Tilray's stock, and shares of other cannabis companies, soared after reports gave investors hope that the Trump administration would move to have marijuana recl...
Cannabis stocks haven't moved like this in years, and it took a rare one-two punch to jolt the sector back to life: a Washington Post scoop hinting that Preside...
Key Points Reports indicate the President will instruct federal agencies to make marijuana a Schedule III drug soon. This isn't "legalization" per se, but it...
It’s not the first (or second or third) time that the Trump administration has been rumored to be considering reclassification. Cannabis stocks are rallying on...
The stock prices of major cannabis companies like Tilray Brands (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC) skyrocketed 34.88% and 27.46%, respectively, in pre...